Drug Profile
Tideglusib - AMO Pharma
Alternative Names: AMO-02; NP-031112; NP-12; Nypta; ZentylorLatest Information Update: 19 Feb 2024
Price :
$50
*
At a glance
- Originator Neuropharma
- Developer AMO Pharma; Brock University; Noscira
- Class Anti-inflammatories; Antidementias; Behavioural disorder therapies; Naphthalenes; Neuroprotectants; Small molecules; Thiadiazoles
- Mechanism of Action Glycogen synthase kinase 3 beta inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II/III Myotonic dystrophy
- Preclinical Duchenne muscular dystrophy
- No development reported Autistic disorder
- Discontinued Alzheimer's disease; Progressive supranuclear palsy
Most Recent Events
- 15 Feb 2024 Hamilton Health Sciences Corporation plans a phase IIPHRI.TaRGET trial for Cardiomyopathies in Canada (PO) in mid year 2024 (NCT06174220)
- 19 Sep 2023 Preclinical trials in Duchenne muscular dystrophy in USA (PO), prior to September 2023
- 19 Sep 2023 Pharmacodynamics data from preclinical trials in Duchenne muscular dystrophy released by AMO Pharma